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Abstract: 
Objectives: Subcutaneous sacral nerve stimulation is recommended by 
NICE as a second line treatment for patients with faecal incontinence who 
failed conservative therapy. Sacral nerve stimulation is an invasive 
procedure associated with complications and re-operations. This study 
aimed to investigate whether delivering less invasive and less costly 
percutaneous tibial nerve stimulation prior to sacral nerve stimulation is 
cost-effective.  
 
Methods: A decision analytic model was developed to estimate the cost-
effectiveness of percutaneous tibial nerve stimulation with subsequent 
subcutaneous sacral nerve stimulation versus subcutaneous sacral nerve 
stimulation alone. The model was populated with effectiveness data from 
systematic reviews and cost data from randomized studies comparing both 
procedures in an NHS setting.  
 
Results: Offering percutaneous tibial nerve stimulation prior to sacral nerve 
stimulation (compared to delivering sacral nerve stimulation straight away) 
was both more effective and less costly in all modeled scenarios. The 
estimated savings from offering percutaneous tibial nerve stimulation first 
were £662 - £5,697 per patient. The probability of this strategy being cost-
effective was around 80% at £20,000 -£30,000 per QALY.  
 
Conclusion: Our analyses suggest that offering patients percutaneous tibial 
nerve stimulation prior to sacral nerve stimulation can be both cost 
effective and cost saving in the treatment of faecal incontinence.  
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Abstract 
Objectives: Subcutaneous sacral nerve stimulation is recommended by NICE as a second 
line treatment for patients with faecal incontinence who failed conservative therapy. Sacral 
nerve stimulation is an invasive procedure associated with complications and reoperations. 
This study aimed to investigate whether delivering less invasive and less costly 
percutaneous tibial nerve stimulation prior to sacral nerve stimulation is cost-effective. 
Methods: A decision analytic model was developed to estimate the cost-effectiveness of 
percutaneous tibial nerve stimulation with subsequent subcutaneous sacral nerve stimulation 
versus subcutaneous sacral nerve stimulation alone. The model was populated with 
effectiveness data from systematic reviews and cost data from randomized studies 
comparing both procedures in an NHS setting. 
Results: Offering percutaneous tibial nerve stimulation prior to sacral nerve stimulation 
(compared to delivering sacral nerve stimulation straight away) was both more effective and 
less costly in all modeled scenarios. The estimated savings from offering percutaneous tibial 
nerve stimulation first were £662 - £5,697 per patient. The probability of this strategy being 
cost-effective was around 80% at £20,000 -£30,000 per QALY. 
Conclusion: Our analyses suggest that offering patients percutaneous tibial nerve 
stimulation prior to sacral nerve stimulation can be both cost effective and cost saving in the 
treatment of faecal incontinence. 
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Introduction 
It is estimated that in the UK the prevalence of faecal incontinence in adults living in the 
community is 1-10%, depending on the definition used1,2. Faecal incontinence affects the 
ability to live a normal life, work and socialize, and has huge emotional impact on patients 
and their carers. Faecal incontinence is associated with high costs to the NHS and society 
due to heavy use of health care services, loss of work productivity, unemployment and 
disability. 
According to the NICE guidelines on managing faecal incontinence2, the first-line treatment 
for faecal incontinence is conservative, such as antidiarrhoeal medication, pelvic floor 
muscle training, bowel retraining, specialist dietary assessment and management, 
biofeedback, electrical stimulation and rectal irrigation. For patients with a weak but 
structurally intact sphincter, in whom sphincter surgery is deemed inappropriate, 
subcutaneous sacral nerve stimulation (SNS) may be the next treatment option. It involves 
an implantation of a stimulator which applies an electric current to one of the sacral nerves 
via an electrode placed through the corresponding sacral foramen3. According to a 
systematic literature review4, 41-75% of implanted patients achieved complete continence 
and 75-100% experienced 50% improvement in the number of faecal incontinence episodes. 
However, the implantation of a stimulator is associated with complications such as pain, lead 
migration, wound infection and loss of effectiveness. The reported pooled incidence of pain 
and infection after implantation was 13.0% and 3.9%, respectively5. Complications may lead 
to removal of the stimulator and subsequent re-implantation. 
Percutaneous tibial nerve stimulation (PTNS) is a less invasive treatment available for 
people with faecal incontinence who do not respond adequately to conservative therapy6. It 
involves electrical stimulation of the posterior tibial nerve via a needle percutaneously 
inserted into the ankle and connected to an external pulse generator. Initial treatment usually 
consists of 12-15 outpatient sessions lasting 30 minutes each, typically a week apart. 
Treatment usually requires two top-up sessions every 6 months. Adverse events are rare 
and resolve spontaneously. PTNS was shown to be less effective in reducing faecal 
incontinence compared to SNS4,7,8 The NICE guidance on percutaneous tibial nerve 
stimulation states that there is limited evidence on the benefits of PTNS, particularly in the 
long term
6
. It recommends that PTNS should only be used “with special arrangements for 
clinical governance, consent and audit or research”
6
. In recent years there has been a 
growing body of evidence demonstrating the effectiveness of PTNS for faecal incontinence, 
including the long-term effects of this procedure4,7-9. In light of these findings, the current 
NICE recommendations on the management of faecal incontinence2,6 should be reviewed. 
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Although PTNS appears to be less effective than SNS, it can be delivered prior to SNS due 
to good acceptance by patients. Patients eligible for SNS could be treated with percutaneous 
tibial nerve stimulation before being considered for sacral nerve stimulation10. The cost-
effectiveness of this strategy is debatable, since patients receiving both treatments incur 
higher costs than people receiving one of the treatments. Comparing the costs of PTNS and 
SNS is not straightforward, given that SNS costs are incurred mainly upfront, while PTNS 
costs incur over time due to maintenance treatments. To enable a comparison between the 
two treatment strategies, a decision-analytic model was developed which compared the 
cost-effectiveness of PTNS followed by SNS upon PTNS failure, versus SNS alone, over a 
five-year time horizon. The model was populated with effectiveness data from published 
studies4,7-21 and the cost data from the randomized pilot study comparing PTNS with SNS in 
an NHS setting22. 
 
Materials and methods 
 
SNS and PTNS treatments 
SNS is delivered in two stages. At the first stage a temporary peripheral nerve electrode is 
inserted under local anesthetic and attached to an external stimulator. Temporary SNS is 
delivered under local anesthetic as an outpatient procedure. The patients will be given 
questionnaires to record their faecal incontinence symptoms during the test period (2-3 
weeks)3. They may develop complications such as pain, wound infection, electrode 
dislocation and loss of effectiveness. Treatment of these complications may include: 
adjusting the stimulator's settings, electrode re-positioning, wound revision, antibiotic 
treatment, removal of electrode, and insertion of new electrode. If faecal incontinence 
symptoms improve during the testing period (2-3 weeks), the permanent lead and the 
permanent stimulator (implant) will be inserted. This procedure is delivered as a day case 
under general anesthetic3. After the operation patients will be prescribed antibiotics and 
painkillers. They will be given a handset to control the stimulator and a diary to record 
symptoms of faecal incontinence. Following implantation patients may develop complications 
such as pain in the stimulation site, wound infection, lead migration and loss of 
effectiveness5,12,15. They may also undergo removal of the device with subsequent re-
iplantation due to having an MRI scan, or to have the battery changed13,23. In accordance 
with NICE guidance2 all patients with faecal incontinence will attend clinic every 6 months to 
review the symptoms. 
PTNS treatment, delivered by a trained nurse, usually consists of 12 outpatient 
sessions lasting 30 minutes each, typically a week apart; treatment may be repeated as 
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required. Adverse events are not included in the model since these are rare, and resolve 
spontaneously6. 
 
Model description 
A decision analytic model was developed in TreeAge Pro Healthcare 2013 (TreeAge 
Software, Williamstown, MA). The patient population included individuals eligible for SNS 
based on NICE criteria 1 for symptom severity and failure of prior conservative therapy2. The 
decision trees for SNS and PTNS are shown in Figure 1. 
PTNS decision model (Figure 1A). Patients who tolerate PTNS treatment will receive 
17 sessions (15 sessions within 3 months plus 2 top-up sessions at 6 months). Patients who 
do not tolerate the treatment (e.g. due to vasovagal response) may discontinue after the first 
session. Those who achieved ≥50% improvement in faecal incontinence will continue 
receiving 2 PTNS sessions every 6 months. Adverse events for PTNS are not included in the 
model given that these were minor and resolved spontaneously. Patients who did not 
achieve a 50% reduction of faecal incontinence after 17 PTNS sessions will proceed to SNS 
(Figure 1B). 
SNS decision model (Figure1B). Patients first receive temporary SNS. They can 
discontinue the treatment due to intolerance or lack of effectiveness. They can also 
experience adverse events such as infection, electrode dislocation and pain. Patients who 
improved their continence in response to temporary SNS will receive permanent SNS. 
Permanent SNS can cause adverse events (e.g. pain, infection, lead dislocation, loss of 
effectiveness). The SNS stimulator may require its battery to be changed. 
The costing perspective was that of the National Health Service (NHS) and Personal 
Social Services in the UK, with a price year of 2012-2013. The list of model inputs and 
assumptions used in the model and correspondent references are shown in Table 1. The 
analysis considered a five-year time horizon. The “success” of treatment was defined as 
≥50% reduction in faecal incontinence episodes per week4. 
 
Probabilities 
The list of probabilities used in the model is shown in Table 1. Probabilities of >50% 
improvement in FI for SNS and PTNS, and a probability of receiving permanent SNS were 
taken from a systematic review4. The overall probabilities of adverse events for temporary 
and permanent SNS were estimated as a sum of probabilities for pain in the stimulation site, 
electrode defect/dislocation and wound infection. Probabilities of individual adverse events 
were taken from Hezler et al. (2006)12. Sensitivity analyses were conducted including overall 
probabilities of adverse events for temporary and permanent SNS taken from published 
studies14,15,17,20. The probability of discontinuation for PTNS was defined as probability of 
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vasovagal response to needle placement during PTNS16. Due to lack of published data on 
the discontinuation rate for temporary SNS, it was assumed to be the same as for PTNS 
(conservative assumption). Probabilities of removal of SNS stimulator due to MRI scan or 
battery change were taken from Tjandra et al. (2008)19 and Hollingshead et al. (2011)13. 
 
Costs 
The costs of delivering SNS and PTNS in an NHS setting were estimated using a micro-
costing approach. Data on the use of healthcare resources were collected in a randomized 
pilot study comparing SNS and PTNS, published elsewhere22. Costs used in the model were 
divided into three categories:  
1. Up-front costs including devices, procedures, consultations and investigations; 
2. Maintenance costs including top-up sessions for PTNS, battery change for SNS, and 
removal of SNS device due to MRI scan; 
3. Costs associated with adverse events for temporary and permanent SNS. The major 
adverse events for both temporary and permanent SNS were: pain in the stimulation 
site (not related to stimulator settings), electrode or lead defect/dislocation, wound 
infection and the loss of effectiveness. It was assumed that all adverse events would 
require electrode removal with or without subsequent electrode replacement. Costs 
associated with management of wound infection also included antibiotic treatment. 
Costs associated with electrode defect (defined as excessive impedance) and 
electrode dislocation included cost of electrode replacement. Loss of effectiveness 
was assumed to involve electrode removal without subsequent replacement. The 
costs of adverse events were calculated by multiplying unit costs associated with 
management of each adverse event by the probability of each adverse event. Costs 
associated with adverse events for PTNS were not included in the model given that 
these adverse events resolve spontaneously. 
Unit costs of SNS and PTNS devices were based on invoices. Unit costs of the SNS and 
PTNS procedures, consultations and investigations were taken from the National Schedule 
of Reference Costs (2011-2012)26. The model assumes that all patients incur investigation 
and examination costs. Patients who proceed to SNS upon failing PTNS will receive 
additional examinations. The model does not include costs associated with 6-monthly review 
meetings, since these apply to all patients with faecal incontinence2. The lists of unit costs 
used in the model are shown in Tables 2-4. 
 
Health utilities 
Health utilities for patients with faecal incontinence, derived using EQ-5D, were taken from 
published studies11,18,21 (Table 1). Due to a lack of published data on disutilities associated 
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with adverse events for SNS, we used utilities for neuropathic pain derived using EQ-5D27. In 
the base case analysis we used disutilities for moderate pain, while in sensitivity analyses 
we used disutilities for mild and severe pain. Disutilities associated with adverse events were 
assumed to be the same for temporary and permanent SNS. In the base case scenario, the 
duration of adverse events was 7 days (the average NHS consultant-led waiting time, NHS 
2013)26. In sensitivity analyses the duration of adverse events was 3 and 14 days. The 
model assumes that patients who discontinued PTNS or SNS with no adverse events have 
the same utility as those who did not achieve ≥50% improvement in faecal incontinence. 
 
Discounting 
Both costs and QALYs were discounted after year one to reflect time preference. In the base 
case analysis both costs and QALYs were discounted at 3.5%29. In sensitivity analyses 
discount rates were 1.5% and 6%29,30. Given that the majority of costs (e.g. associated with 
devices, procedures, and adverse events) were incurred in year one, the discounting was 
applied to maintenance costs only. 
 
Cost-effectiveness analysis 
The economic analysis complied with the NICE reference case29, and is reported according 
to the Consolidated Health Economic Evaluation Reporting Standards (CHEERS)31. The 
primary outcome of the model was the incremental cost-effectiveness ratio (cost per QALY 
gained). Univariate sensitivity analysis was conducted to assess uncertainty associated with 
probability of receiving permanent SNS; probabilities of >50% improvement in faecal 
incontinence for SNS and PTNS; probabilities of adverse events for temporary and 
permanent SNS; health utility for adverse events; duration of adverse events and costs of 
SNS and PTNS. A probabilistic sensitivity analysis was undertaken to assess the joint 
uncertainty in costs and QALYs32. Probability distributions were assigned to probabilities, 
QALYs and costs and 10,000 Monte-Carlo simulations were conducted to calculate the 
probability of cost-effectiveness at the NICE threshold of £30,000 per QALY gained29. 
 
Results 
 
Costs 
The up-front and maintenance costs associated with PTNS are summarised in Table 2. The 
up-front cost, which included costs of device, consultations, investigations and 15 PTNS 
procedures, was £2,579 per patient. The cost of two maintenance PTNS procedures was 
£268 (£535 a year). Analysis assumes one stimulator per 10 patients (15 sessions for each 
patient) and 15 leads per patient, as per trial22. The life-time of a UPC stimulator was 
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assumed to be five years. The total cost of delivering PTNS in year one was £2,847, and 
£4,988 over five years. Patients who discontinued PTNS due to intolerance incurred cost of 
£619, which included costs of consultations, investigations and one PTNS procedure. No 
costs related to adverse events were included, since adverse events for PTNS were minor 
and transient. The major PTNS costs were associated with clinic attendances to receive 
PTNS sessions.  
 Unit costs for SNS are summarized in Table 3. The up-front costs for SNS included 
costs of consultations , investigations and procedures for temporary and permanent SNS. 
The total up-front cost of SNS was £13,829 which included the cost of temporary SNS 
(£1,613) and the cost of permanent SNS (£12,216). All devices were considered to be single 
use, except for the power source for temporary SNS, which was assumed to be shared by 
18 patients, as per trial22. Maintenance costs included costs associated with battery change 
and MRI scan (Table 3), which would require removing the existing device and inserting a 
new one. Maintenance costs were calculated by multiplying unit costs by the probabilities of 
needing an MRI scan or battery change. The estimated maintenance cost over five-year 
period was £1,004 per person. The break-down of costs associated with adverse events for 
SNS are shown in Table 4. The total cost of adverse events over 5 years multiplied by their 
probabilities (Table 1) was £156 per patient for temporary SNS, and £880 for permanent 
SNS. The main SNS costs were associated with the SNS device, followed by operation 
procedures. 
The total PTNS and SNS costs over 5 years (including costs of adverse events and 
maintenance) are summarized in Appendix 1. These varied in the range £2,847 - £4,849 for 
PTNS, £13,829 - £19,153.28 for SNS, and £16,676 - £22,000 for PTNS+SNS (Appendix 1). 
 
QALYs 
Total QALYs used in the model are summarized in Table 5. Patients who achieved ≥50% 
improvement in faecal incontinence in the absence of adverse events generated 3.454 
QALYs over 5 years, while patients who did improve their symptoms had a QALY value of 
3.095 (3.5% discounting). This difference equals 131 days with improved continence. 
Adverse events had a small effect on total QALYs due to their transient character. The total 
QALYs were sensitive to the discounting rate, while changes in the duration of adverse 
events had only a very minor effect (Table 5).  
 
Cost-utility analysis 
In the base case scenario (Table 6) the total cost of the PTNS+SNS treatment strategy was 
£8,619 over five years, and the cost of the SNS strategy was £12,386 (difference in cost 
-£3,767). The total QALYs for patients receiving PTNS+SNS treatment were 3.379, and for 
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SNS 3.310 (difference in QALY 0.070). The PTNS+SNS treatment strategy was less costly 
and marginally more effective compares to the SNS strategy. 
Univariate sensitivity analysis was conducted to address variation in model parameters 
(Table 6). Results of sensitivity analyses demonstrate that PTNS+SNS remained less costly 
and more effective in all scenarios. The difference in costs between the two strategies varied 
from £662 to £5.697 per participant over five years. The difference in QALYs varied from 
0.029 to 0.135. The model was most sensitive to the probability of receiving permanent SNS 
following temporary SNS. Nevertheless, PTNS+SNS remained the dominant strategy even 
when the probability of receiving permanent SNS was set to 1.  
Probabilistic sensitivity analysis was conducted to assess joint variation on model 
parameters using Monte-Carlo simulations. Probability distributions assigned to model 
parameters are summarized in Appendix 2. The cost-effectiveness plane and the cost-
effectiveness acceptability curve are shown in Figure 2. Figure 2A shows a plot of 1,000 
simulations of incremental cost against incremental QALYs. Almost all simulations fell within 
the south quadrants, indicating that the PTNS+SNS treatment strategy was less costly 
compared to the SNS only. The ellipse on the graph shows 95% confidence intervals for the 
incremental cost-effectiveness ratio. The line shows the NICE willingness-to-pay threshold at 
£30,000 per QALY gained. Figure 2B shows the cost-effectiveness acceptability at different 
willingness-to-pay values. The probability of the PTNS+SNS treatment strategy being cost-
effective at £20,000 - £30,000 per QALY gained was around 80%. 
 
Discussion 
The majority of economic evaluations in healthcare are focused on assessing the cost-
effectiveness of alternative treatment options. Cost-effectiveness is the major driver of NICE 
decisions (82%), although other factors, such as clinical evidence, play an important role33. 
The benefits of PTNS for people with faecal incontinence have been questioned34,35 due to 
the lack of pronounced clinical effects compared with a sham treatment36,37. It has been 
concluded that percutaneous tibial nerve stimulation is unlikely to be recommended over 
sacral nerve stimulation35. However, in real life, patients may prefer treatments which are 
less effective (although well tolerated) before considering more effective options10. 
 In this study we looked at two treatment options, SNS and PTNS, for patients with 
faecal incontinence who do not respond adequately to conservative therapy. SNS has been 
previously shown to be more effective and more costly compared to PTNS, at least in the 
short term. However, comparing two strategies is not straightforward. Firstly, the majority of 
SNS costs are incurred up-front, while PNTS requires repeated treatments over time. 
Secondly, SNS is delivered in two stages and proceeding to the second stage depends on 
the outcome of the first stage. Thirdly, in the long-term, SNS may require reoperations due to 
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the loss of effectiveness with time, battery change or the need of MRI scan. Fourthly, 
patients may first try PTNS before moving to SNS. Although PTNS appears to be less 
effective compared to SNS, it is less invasive, and therefore more appealing to patients. The 
long-term effectiveness of PTNS for faecal incontinence is still to be proved, although a 
sustained therapeutic effect of PTNS was demonstrated for up to 42 months9. Due to a lack 
of long-term data for both SNS and PTNS, we limited our analysis to a five-year time 
horizon. Within this time horizon the PTNS+SNS strategy was less costly and more effective 
compared to SNS alone. The probability of PTNS+SNS being cost effective was around 80% 
within the NICE cut-off range of £30,000 per QALY (Figure 2). 
 Being model-based, this study has a number of limitations. First, we limited the 
number of adverse events for SNS to two, and the number of reoperations to one. We also 
assumed that there will be no hospitalisations associated with adverse events for SNS. As a 
matter of course, we based our model on conservative assumptions: 
1. In the base case analysis the probability of ≥50% improvement for PTNS was set to the 
lowest value; 
2. Initial PTNS treatment included 15 sessions, 30-min each, as per trial28, while NICE 
recommends 12 PTNS sessions, 30-min each22. 
3. The probability of discontinuation for SNS was assumed to be the same as for PTNS; 
4. It was assumed that the treatment of adverse events associated with SNS will require only 
one outpatient attendance, which may be not the case in real life.  
 Our estimations of SNS and PTNS costs are in general agreement with previous 
studies, except that the latter did not include costs associated with reoperations, adverse 
events and loss of effectiveness with time. A cost-effectiveness model commissioned by the 
Department of Health38 showed that total SNS cost over 10 years was £12,847 per person, 
compared to the cost of conservative management of £3,705 per person. A study by 
Hotouras et al.39 showed that the one year cost of SNS was £11,374 and for PTNS £1,740. 
According to our estimations, the cost of SNS ranges from £13,829 to £19,153.28 and the 
costs of PTNS from £2,847 to £4,849 per person over 5 years (Appendix 1). The 
conservative estimate is that 41% of patients will not benefit from PTNS4 and subsequently 
receive SNS. For this group of patients, the total cost of PTNS+SNS treatment will be in the 
range £16,676 to £22,000 over 5 years (Appendix 1). A number of sensitivity analyses 
conducted by varying costs, probabilities and utilities (Table 5) showed that offering PTNS 
prior to SNS is both less costly and more effective compared to SNS on its own.  
The attractiveness of PTNS is that it can be self-administered (by at least a fraction of 
patients), which could reduce costs associated with maintenance treatments. The home-
based PTNS was piloted in 9 patients; six of them reported an improvement in faecal 
incontinence, anxiety and depression40. 
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 In summary, the results of our study demonstrate that delivering PTNS prior to SNS 
in the treatment of faecal incontinence can be both cost-effective and cost-saving compared 
to delivering SNS alone. Offering PTNS would reduce the need for SNS treatments, or at 
least delay these. It would decrease the costs associated with SNS complications. The 
savings can be up to £5,697 per patient over 5 years. Our results suggest that the probability 
of this strategy being cost-effective is around 80%. 
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Table 1. List of parameters used in the model 
 
Parameter  Value Reference  
Probabilities: PTNS   
Probability of >50% improvement in FI for PTNS   
     base case 0.59 Thin et al. 2013
4
 
     lower limit 0.59 Thin et al. 2013
4
 
     upper limit 0.71 Thin et al. 2013
4
 
Probability of discontinuation for PTNS 0.04 Peters et al. 2009
16
 
Probability of proceeding to SNS after failing PTNS   
     base case 
0.96 
Assumption: probability of not proceeding to SNS 
equal to probability of discontinuation for PTNS 
     lower limit 0.50 Assumption 
     upper limit 1.00 Assumption 
Probabilities: SNS   
Probability of receiving permanent SNS   
     base case 0.77 Thin et al. 2013
4
 
     lower limit 0.40 Thin et al. 2013
4
 
     upper limit 1.00 Thin et al. 2013
4
 
Probability of >50% improvement in FI for permanent SNS 
(short-term)   
     base case 0.79 Thin et al. 2013
4
 
     lower limit 0.69 Thin et al. 2013
4
 
     upper limit 0.83 Thin et al. 2013
4
 
Probability of >50% improvement in FI for permanent SNS 
(long-term)   
     base case 0.84 Thin et al. 2013
4
 
     lower limit 0.75 Thin et al. 2013
4
 
     upper limit 1.00 Thin et al. 2013
4
 
Probabilities: Adverse events temporary SNS   
     base case 0.22 
 
Hetzer et al. 2006
12
 (joint probability of adverse 
events: pain in the stimulation site 0.06, wound 
infection 0.08, electrode defect /dislocation 0.08) 
     lower limit 0.02 Prapasrivorakul et al. 2014
17
 
     upper limit 0.35 van Kerrebroeck et al. 2007
20
 
Probabilities: Adverse events permanent SNS   
     base case 
0.35 
Hetzer et al. 2006
12
 (joint probability of adverse 
events: pain in the stimulation site 0.17, wound 
infection 0.09, electrode dislocation 0.09) 
     lower limit 0.13 Jarrett et al. 2004
14
 
     upper limit 0.38 Mellgren 2011
15
 
Probabilities: Maintenance SNS   
Battery change 0.08 Hollingshead et al. 2011
13
 
MRI scan: 0.02 Tjandra et al. 2008
19
 
Health utilities   
Persistent FI    
     base case 0.69 Harvie et al. 2011
11
 
     lower limit 0.56 Soria-Aledo et al. 2011
18
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     upper limit 0.68 van Wunnik et al. 2012
21
 
>50% reduction in FI    
     base case 0.77 Harvie et al 2011
11
 
     lower limit 0.63 Soria-Aledo et al 2011
18
 
     upper limit 0.86 van Wunnik et al 2012
21
 
Adverse events   
     base case 0.46 McDermott et al. 2006
27
 (pain severity: moderate) 
     lower limit 0.67 McDermott et al. 2006
27
 (pain severity: mild) 
     upper limit 0.16 McDermott et al. 2006
27
 (pain severity: severe) 
Adverse event duration   
     base case 
7 days 
NHS England. Consultant-led Referral to Treatment 
Waiting Times. Annual Report (2013)
28
 
     lower limit 3 days Assumption 
     upper limit 14 days Assumption 
Discounting rate   
     base case 3.5% NICE 2013
29
 
     lower limit 1.5% NICE 2013
29
 
     upper limit 6.0% Claxton et al. 2011
30
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Table 2. Unit costs for PTNS 
 
Expenditure type 
Unit cost 
(£) 
Cost per 
patient (£) 
References and assumptions  
Device     
UPC stimulator 868.84 86.88 
Uroplasty 2013 (personal communication). Multiple 
use, 10 patients per stimulator 
UPC lead  417.88 522.35 
Uroplasty 2013 (personal communication). Single 
use, 15 leads per patient 
Procedures      
Consultation 123 123 
NHS Reference Costs
26
. Consultant Led: First 
Attendance Non-Admitted Face to Face, Colorectal 
Surgery 
Physiology testing:      
     Outpatient appointment 99 99 
NHS Reference Costs
26
. Non-Consultant Led: 
Follow up Attendance Non-Admitted Face to Face, 
Colorectal Surgery 
     Ultrasound 51 51 
NHS Reference Costs
26
. Diagnostic Imaging: 
Outpatient. Ultrasound Scan, less than 20 minutes 
     Fluoroscopy 119 119 
NHS Reference Costs
26
.Diagnostic Imaging: 
Outpatient. Contrast Fluoroscopy Procedures, less 
than 20 minutes 
Second consultation 93 93 
NHS Reference Costs
26
. Consultant Led: Follow up 
Attendance Non-Admitted Face to Face, Colorectal 
Surgery 
15 PTNS procedures 99 1,485.00 
NHS Reference Costs
26
. Non-Consultant Led: 
Follow up Attendance Non-Admitted Face to Face, 
Colorectal Surgery 
Up-front cost  2,579.23  
Maintenance     
UPC lead 417.88 69.65 
Uroplasty 2013 (personal communication). Single 
use, 2 leads per patient 
2 top-up PTNS procedures 99 198.00 
NHS Reference Costs
26
. Non-Consultant Led: 
Follow up Attendance Non-Admitted Face to Face, 
Colorectal Surgery 
Maintenance cost over 5 years  2,408.82  
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Table 3. Unit costs for SNS 
 
Expenditure type 
Unit cost 
(£) 
Cost per 
patient (£) 
References and assumptions  
Device     
Temporary SNS     
Temporary SNS kit (includes 2x9cm 
needles) 
210 210 
Medtronic 2013 (personal communication). Single 
use. 
12.5 cm needles pack of 6 135 0.45 
Medtronic 2013 (personal communication).Single 
use, assumes 2 needles per patient, requires for 1% 
of patients 
Power source  335 18.61 
Medtronic 2013 (personal communication). Multiple 
use, assumes 18 patients as per trial 
Permanent SNS     
Patient programmer  500 500 
Medtronic 2013 (personal communication). Single 
use  
Pulse generator  5,700.00 5,700.00 
Medtronic 2013 (personal communication). Single 
use  
Tined lead  1,350.00 1,350.00 
Medtronic 2013 (personal communication). Single 
use  
Lead introducer kit  200 200 
Medtronic 2013 (personal communication). Single 
use  
Procedures       
Temporary SNS     
Initial consultation 123 123 
NHS Reference Costs
26
. Consultant Led: First 
Attendance Non-Admitted Face to Face, Colorectal 
Surgery 
Physiology testing:     
     Outpatient appointment 99 99 
NHS Reference Costs
26
. Non-Consultant Led: 
Follow up Attendance Non-Admitted Face to Face, 
Colorectal Surgery 
     Ultrasound 51 51 
NHS Reference Costs
26
. Diagnostic Imaging: 
Outpatient. Ultrasound Scan, less than 20 minutes 
     Fluoroscopy 119 119 
NHS Reference Costs
26
. Diagnostic Imaging: 
Outpatient. Contrast Fluoroscopy Procedures, less 
than 20 minutes 
Second consultation 93 93 
NHS Reference Costs
26
. Consultant Led: Follow up 
Attendance Non-Admitted Face to Face, Colorectal 
Surgery 
Counseling 99 99 
NHS Reference Costs
26
. Non-Consultant Led: 
Follow up Attendance Non-Admitted Face to Face, 
Colorectal Surgery  
Pre-assessment for operation 99 99 
NHS Reference Costs
26
. Non-Consultant Led: 
Follow up Attendance Non-Admitted Face to Face, 
Colorectal Surgery 
Procedure 599 599 
NHS Reference Costs
26
. Intermediate pain 
procedure, day case 
Post-operative medication: paracetamol 
500mg for 7 days 
2.88 2.88 
BNF 2014. Non-proprietary, 0.5–1 g every 4–6 
hours 
Specialist nurse review 99 99 
NHS Reference Costs
26
. Non-Consultant Led: 
Follow up Attendance Non-Admitted Face to Face, 
Colorectal Surgery 
Permanent SNS     
Pre-assessment for operation 99 99 
NHS Reference Costs
26
. Non-Consultant Led: 
Follow up Attendance Non-Admitted Face to Face, 
Colorectal Surgery 
Procedure 4,268.00 4,268.00 NHS Reference Costs
26
. Insertion of neurostimulator 
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or intrathecal drug delivery device, day case 
Post-operative medication:     
     Co-codamol 8/500 mg for 14 days 3.4 3.4 
BNF 2014. Non-proprietary, 100-tab pack, 1–2 
tablets every 4–6 hours 
     Co-amoxiclav 500/125 mg for 5 days 3.03 3.03 
BNF 2014. Sandoz, 21-tab pack, one tablet every 
12 hours 
Post-operation check at 6 weeks 93 93 
NHS Reference Costs
26
. Consultant Led: Follow up 
Attendance Non-Admitted Face to Face, Colorectal 
Surgery 
    
Total cost temporary SNS  1,612.94  
Total cost permanent SNS  12,216.43  
Maintenance    
Battery change:    
     Removal of device 599 35.94 
NHS Reference Costs
26
. Intermediate pain 
procedure, day case  
     Re-implantation 4,268.00 256.08 
NHS Reference Costs
26
. Insertion of neurostimulator 
or intrathecal drug delivery device, day case 
     New device 7,750.00 465.00 
Cost of device for permanent SNS (see top of this 
table) 
MRI scan:    
     Removal of device 599 11.09 
NHS Reference Costs
26
. Intermediate pain 
procedure, day case 
     Re-implantation 4,268.00 79.04 
NHS Reference Costs
26
. Insertion of neurostimulator 
or intrathecal drug delivery device, day case 
     New device 7,750.00 143.52 
Cost of device for permanent SNS (see top of this 
table) 
Consultation 93 7.44 
NHS Reference Costs
26
.Consultant Led: Follow up 
Attendance Non-Admitted Face to Face, Colorectal 
Surgery 
Post-operative medication:    
     Co-codamol 8/500 mg for 14 days 3.4 0.27 
BNF 2014. Non-proprietary, 1–2 tablets every 4–6 
hours 
     Co-amoxiclav 500/125 mg for 5 days 3.03 0.24 BNF 2014. Sandoz, one tablet every 12 hours 
Post-operation check  93 7.44 
NHS Reference Costs
26
. Consultant Led: Follow up 
Attendance Non-Admitted Face to Face, Colorectal 
Surgery 
Maintenance cost over 5 years  1,004  
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Table 4. Unit costs of adverse events for SNS 
 
Event Unit cost Cost per 
person 
Reference/assumption 
Temporary SNS 
Electrode defect/dislocation   
Consultation 93 46.50 NHS Reference Costs
26
. Consultant Led: Follow 
up Attendance Non-Admitted Face to Face, 
Colorectal Surgery 
Electrode replacement  599 299.50 NHS Reference Costs
26
. Intermediate pain 
procedure, day case 
New electrode 210 52.50 Medtronic 2013 (personal communication).  
Paracetamol 500mg for 7 days 2.88 1.44 BNF 2014. Non-proprietary, 0.5–1.0g every 4–6 
hours 
Pain in the stimulation site 
Consultation 93 11.63 NHS Reference Costs
26
. Consultant Led: Follow 
up Attendance Non-Admitted Face to Face, 
Colorectal Surgery 
Electrode re-positioning 599 74.88 NHS Reference Costs
26
. Intermediate pain 
procedure, day case 
New electrode 210 13.13 Medtronic 2013 (personal communication).. 
Paracetamol 500mg for 7 days 2.88 0.36 BNF 2014. Non-proprietary, 0.5–1.0g every 4–6 
hours 
Wound infection 
Consultation 93 11.63 NHS Reference Costs
26
. Consultant Led: Follow 
up Attendance Non-Admitted Face to Face, 
Colorectal Surgery 
Wound revision/removal of electrode 599 74.88 NHS Reference Costs
26
. Consultant Led: Follow 
up Attendance Non-Admitted Face to Face, 
Colorectal Surgery 
Co-amoxiclav 500/125 mg for 5 days 3.03 0.38 BNF 2014. Sandoz, one tablet every 12 hours 
Paracetamol 500mg for 7 days 2.88 0.36 BNF 2014. Non-proprietary, 0.5–1.0g every 4–6 
hours 
Post-operation check 93 11.63 NHS Reference Costs
26
. Consultant Led: Follow 
up Attendance Non-Admitted Face to Face, 
Colorectal Surgery 
Re-implantation of electrode 599 74.88 NHS Reference Costs
26
. Intermediate pain 
procedure, day case 
New electrode 210 13.13 Medtronic 2013 (personal communication). 
Loss of effectiveness 
       Removal of electrode 93 23.25 NHS Reference Costs
26
. Consultant Led: Follow 
up Attendance Non-Admitted Face to Face, 
Colorectal Surgery 
Cost of adverse events for temporary SNS 
adjusted for probability (Table 1) 
 156.21  
Permanent SNS 
Electrode dislocation 
Consultation 93 34.88 NHS Reference Costs
26
. Consultant Led: Follow 
up Attendance Non-Admitted Face to Face, 
Colorectal Surgery 
 Re-positioning of electrode 4,268.00 1600.50 NHS Reference Costs
26
. Insertion of 
neurostimulator or intrathecal drug delivery device, 
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day case 
Post-operative medication    
       Co-codamol 8/500 mg for 14 days 3.4 1.28 BNF 2014. Non-proprietary, 100-tab pack, 1–2 
tablets every 4–6 hours 
       Co-amoxiclav 500/125 mg for 5 days 3.03 1.14 BNF 2014. Sandoz, 21-tab pack, one tablet every 
12 hours 
Post-operation check 93 34.88 NHS Reference Costs
26
. Consultant Led: Follow 
up Attendance Non-Admitted Face to Face, 
Colorectal Surgery 
Pain in the stimulation site 
Consultation 93 11.63 NHS Reference Costs
26
. Consultant Led: Follow 
up Attendance Non-Admitted Face to Face, 
Colorectal Surgery 
Re-positioning of device 599 74.88 NHS Reference Costs
26
. Intermediate pain 
procedure, day case 
Paracetamol 500mg for 7 days 2.88 0.36 BNF 2014. Non-proprietary, 0.5–1.0g every 4–6 
hours 
 Post-operation check 93 11.63 NHS Reference Costs
26
. Consultant Led: Follow 
up Attendance Non-Admitted Face to Face, 
Colorectal Surgery 
Wound infection 
Consultation 93 34.88 NHS Reference Costs
26
. Consultant Led: Follow 
up Attendance Non-Admitted Face to Face, 
Colorectal Surgery 
Wound revision/device removal 599 224.63 NHS Reference Costs
26
. Intermediate pain 
procedure, day case  
Post-operative medication    
       Co-codamol 8/500 mg for 14 days 3.4 0.43 BNF 2014. Non-proprietary, 100-tab pack, 1–2 
tablets every 4–6 hours 
       Co-amoxiclav 500/125 mg for 5 days 3.03 0.38 BNF 2014. Sandoz, 21-tab pack, one tablet every 
12 hours 
Post-operation check 93 34.88 NHS Reference Costs
26
. Consultant Led: Follow 
up Attendance Non-Admitted Face to Face, 
Colorectal Surgery 
Re-implantation 4,268.00 533.50 NHS Reference Costs
26
. Insertion of 
neurostimulator or intrathecal drug delivery device, 
day case 
New device 7,750.00 968.75 Cost of device for permanent SNS (see Table 3) 
Post-operative medication    
       Co-codamol 8/500 mg for 14 days 3.4 0.43 BNF 2014. Non-proprietary, 100-tab pack, 1–2 
tablets every 4–6 hours 
       Co-amoxiclav 500/125 mg for 5 days 3.03 0.38 BNF 2014. Sandoz, 21-tab pack, one tablet every 
12 hours 
Post-operation check 93 11.63 NHS Reference Costs
26
. Consultant Led: Follow 
up Attendance Non-Admitted Face to Face, 
Colorectal Surgery 
Loss of effectiveness    
Consultation 93 11.63 NHS Reference Costs
26
. Consultant Led: Follow 
up Attendance Non-Admitted Face to Face, 
Colorectal Surgery 
Removal of device 599 74.88 NHS Reference Costs
26
. Intermediate pain 
procedure, day case  
Paracetamol 500mg for 7 days 2.88 0.36 BNF 2014. Non-proprietary, 0.5–1.0g every 4–6 
hours 
Cost of adverse events for permanent 
SNS adjusted for probability (Table 1) 
 880.28  
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Table 5. QALYs over five-year period calculated using different discounting rate and 
different duration of adverse events 
 
Treatment scenario 
Discounting rate 
1.5% 3.5% 6% 
SNS                                                                                                       QALY 
≥50% improvement in faecal incontinence    
No adverse events  3.672 3.454 3.210 
One adverse event 3.663 3.445 3.201 
Two adverse events 3.654 3.436 3.192 
<50% improvement in faecal incontinence 
No adverse events  3.290 3.095 2.876 
One adverse event 3.282 3.086 2.867 
Two adverse events 3.273 3.078 2.859 
PTNS    
≥50% improvement in faecal incontinence 3.672 3.454 3.210 
<50% improvement in faecal incontinence 3.290 3.095 2.876 
Treatment scenario 
Duration of adverse events (discounting rate 3.5%) 
3 days 7 days 14 days 
SNS                                                                                                        QALY 
≥50% improvement in faecal incontinence 
One adverse event 3.450 3.445 3.436 
Two adverse events 3.446 3.436 3.419 
<50% improvement in faecal incontinence 
One adverse event 3.370 3.365 3.356 
Two adverse events 3.366 3.356 3.339 
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Table 6. Results of cost-utility analyses  
 
Parameter 
Difference in 
cost, £ 
Difference in 
QALY ICER 
Base case -3,767 0.070 PTNS+SNS dominates 
Probability of >50% improvement in FI for PTNS  
     base case 0.59 
    
     lower limit: 0.59 -3,767 0.070 PTNS+SNS dominates 
     upper limit:0.71 -4,968 0.087 PTNS+SNS dominates 
Probability of receiving permanent SNS 
     base case 0.77 
   
     lower limit: 0.4 -662 0.135 PTNS+SNS dominates 
     upper limit: 1.0 -5,697 0.029 PTNS+SNS dominates 
Probability of >50% improvement in FI for permanent SNS 
     base case 0.79 
   
     lower limit  0.69 -3,725 0.087 PTNS+SNS dominates 
     upper limit  0.83 -3,784 0.063 PTNS+SNS dominates 
Probability of proceeding to SNS after failing PTNS 
     base case 0.96 
   
      lower limit 0.50 -6,078 0.031 PTNS+SNS dominates 
      upper limit 1.0 -3,566 0.073 PTNS+SNS dominates 
Overall probability of adverse events for temporary SNS 
     base case 0.22 
   
     lower limit: 0.02 -3,809 0.069 PTNS+SNS dominates 
     upper limit: 0.35 -3,739 0.070 PTNS+SNS dominates 
Overall probability of adverse events for permanent SNS 
     base case 0.24 
   
     lower limit: 0.13 -3,553 0.069 PTNS+SNS dominates 
     upper limit: 0.38 -4,039 0.070 PTNS+SNS dominates 
Utility for adverse events 
     base case 0.46  
   
     lower limit: 0.16 -3,767 0.068 PTNS+SNS dominates 
     upper limit: 0.67 -3,767 0.071 PTNS+SNS dominates 
Duration of adverse events 
     base case 7 days 
   
     lower limit: 3 days -3,767 0.069 PTNS+SNS dominates 
     upper limit: 14 days -3,767 0.072 PTNS+SNS dominates 
Cost of temporary SNS procedure 
     base case £599 
   
     lower limit: £338 -3,554 0.070 PTNS+SNS dominates 
     upper limit: £710 -3,861 0.070 PTNS+SNS dominates 
Cost of permanent SNS procedure 
     base case £4,280 
   
     lower limit: £1,373 -2,209 0.070 PTNS+SNS dominates 
     upper limit: £5,627 -4,498 0.070 PTNS+SNS dominates 
Cost of PTNS procedure 
     base case £99 
   
     lower limit: £53 -4,876 0.070 PTNS+SNS dominates 
     upper limit: £111 -3,477 0.070 PTNS+SNS dominates 
Discounting rate  
     base case 3.5% 
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     lower limit: 1.5% -3,697 0.074 PTNS+SNS dominates 
     upper limit: 6.0% -3,845 0.065 PTNS+SNS dominates 
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Figure 1. Decision trees for PTNS (A) and SNS (B)  
 
140x122mm (300 x 300 DPI)  
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Figure 2. The cost-effectiveness plane (A) and the cost-effectiveness acceptability curve (B) for the base-
case scenario  
 
127x169mm (300 x 300 DPI)  
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Appendix 1. Costs used in the model (£), discounted after year one 
 
 
1.5% 
discounting 
3.5% 
discounting 
6% 
discounting 
PTNS    
≥50% improvement 4,848.79 4,678.38 4,487.25 
No improvement 2,846.88 2,846.88 2,846.88 
Discontinued 618.82 618.82 618.82 
SNS    
Temporary SNS, no adverse events 1,612.94 1,612.94 1,612.94 
Temporary SNS, adverse events 2,322.98 2,322.98 2,322.98 
Permanent SNS, no adverse events, ≥50% improvement 14,775.38 14,704.35 14,624.68 
Permanent SNS, no adverse events, no improvement 13,829.37 13,829.37 13,829.37 
Temporary SNS with adverse events + permanent SNS with adverse 
events, ≥50% improvement 19,153.28 19,082.25 19,002.58 
Temporary SNS with adverse events + permanent SNS with adverse 
events, no improvement 18,207.27 18,207.27 18,207.27 
Temporary SNS with adverse events + permanent SNS no adverse 
events, ≥50% improvement 15,485.41 15,414.38 15,334.71 
Temporary SNS with adverse events + permanent SNS no adverse 
events, no improvement 14,539.41 14,539.41 14,539.41 
Temporary SNS no adverse events + permanent SNS with adverse 
events, ≥50% improvement 18,443.24 18,372.21 18,292.54 
Temporary SNS no adverse events + permanent SNS with adverse 
events, no improvement 17,497.23 17,497.23 17,497.23 
PTNS+SNS    
PTNS + temporary SNS, no adverse events 4,459.82 4,459.82 4,459.82 
PTNS + temporary SNS, adverse events 5,169.86 5,169.86 5,169.86 
PTNS + permanent SNS, no adverse events, ≥50% improvement 17,622.26 17,551.23 17,471.56 
PTNS + permanent SNS, no adverse events, no improvement 16,676.25 16,676.25 16,676.25 
PTNS + temporary SNS with adverse events + permanent SNS with 
adverse events, ≥50% improvement 22,000.16 21,929.13 21,849.46 
PTNS + temporary SNS with adverse events + permanent SNS with 
adverse events, no improvement 21,054.15 21,054.15 21,054.15 
PTNS + temporary SNS with adverse events + permanent SNS no 
adverse events, ≥50% improvement 18,332.29 18,261.27 18,181.60 
PTNS + temporary SNS with adverse events + permanent SNS no 
adverse events, no improvement 17,386.29 17,386.29 17,386.29 
PTNS + temporary SNS no adverse events + permanent SNS with 
adverse events, ≥50% improvement 21,290.12 21,219.09 21,139.42 
PTNS + temporary SNS no adverse events + permanent SNS with 
adverse events, no improvement 20,344.11 20,344.11 20,344.11 
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Appendix 2. Model parameters used fin probabilistic analysis 
 
Parameters mean SD distribution alpha beta 
Probabilities 
PTNS ≥50% improvement 0.6200 0.0300 beta 161.6822 99.0956 
Proceeding to permanent SNS 0.7350 0.1500 beta 5.6277 2.0290 
SNS_≥50% improvement 0.7750 0.0350 beta 109.5439 31.8031 
Adverse events for temporary SNS 0.2039 0.0828 beta 4.6281 18.0740 
Adverse events for permanent SNS 0.2487 0.0625 beta 11.6484 35.1864 
QALY 
PTNS ≥50% improvement 3.3743 0.5087 normal 44.0037 13.0407 
PTNS discontinued 2.8793 0.3233 normal 79.3048 27.5434 
Temporary SNS_adverse_no_implant 2.8710 0.3191 normal 80.9752 28.2043 
QALY_TempSNS_no_adverse_no_implant 2.8793 0.3233 normal 79.3048 27.5434 
QALY_PermSNS_adverse2_improved 3.3579 0.4989 normal 45.3080 13.4931 
QALY_PermSNS_adverse2_not_improved 2.8628 0.3148 normal 82.6991 28.8878 
QALY_PermSNS_adverse1_improved 3.3743 0.5087 normal 44.0037 13.0407 
QALY_PermSNS_adverse1_not_improved 2.8710 0.3191 normal 80.9752 28.2043 
QALY_PermSNS_no_adverse_not_improved 2.8793 0.3233 normal 79.3048 27.5434 
QALY_PermSNS_no_adverse_improved 3.3743 0.5087 normal 44.0037 13.0407 
Costs PTNS 
≥50% improvement 4,040.61 715.54 gamma 31.8881 0.0079 
No improvement 2,364.21 422.01 gamma 31.3860 0.0133 
Discontinued 607.49 30.62 gamma 393.7170 0.6481 
Costs SNS 
Temporary SNS, no adverse events 1,562.94 190.97 gamma 66.9787 0.0429 
Temporary SNS, adverse events 2,229.23 358.08 gamma 38.7578 0.0174 
Permanent SNS, no adverse events, ≥50% 
improvement 14,103.89 2,525.38 gamma 31.1906 0.0022 
Permanent SNS, no adverse events, no improvement 13,267.37 2,363.65 gamma 31.5067 0.0024 
Temporary SNS with adverse events + permanent 
SNS with adverse events, ≥50% improvement 18,150.79 3,898.14 gamma 21.6808 0.0012 
Temporary SNS with adverse events + permanent 
SNS with adverse events, no improvement 17,314.27 3,736.41 gamma 21.4733 0.0012 
Temporary SNS with adverse events + permanent 
SNS no adverse events, ≥50% improvement 14,770.18 2,692.45 gamma 30.0937 0.0020 
Temporary SNS with adverse events + permanent 
SNS no adverse events, no improvement 13,933.66 2,530.72 gamma 30.3140 0.0022 
Temporary SNS no adverse events + permanent 
SNS with adverse events, ≥50% improvement 17,484.51 3,731.08 gamma 21.9603 0.0013 
Temporary SNS no adverse events + permanent 
SNS with adverse events, no improvement 16,647.98 3,569.34 gamma 21.7544 0.0013 
Costs PTNS+SNS 
PTNS + temporary SNS, no adverse events 3,927.15 521.86 gamma 56.6305 0.0144 
PTNS + temporary SNS, adverse events 4,593.44 643.92 gamma 50.8871 0.0111 
PTNS + permanent SNS, no adverse events, ≥50% 
improvement 16,468.11 2,697.60 gamma 37.2677 0.0023 
PTNS + permanent SNS, no adverse events, no 
improvement 15,631.58 2,537.74 gamma 37.9412 0.0024 
PTNS + temporary SNS with adverse events + 
permanent SNS with adverse events, ≥50% 20,515.01 4,060.83 gamma 25.5219 0.0012 
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improvement 
PTNS + temporary SNS with adverse events + 
permanent SNS with adverse events, no 
improvement 19,678.49 3,899.93 gamma 25.4607 0.0013 
PTNS + temporary SNS with adverse events + 
permanent SNS no adverse events, ≥50% 
improvement 17,134.39 2,863.45 gamma 35.8063 0.0021 
PTNS + temporary SNS with adverse events + 
permanent SNS no adverse events, no improvement 16,297.87 2,703.40 gamma 36.3447 0.0022 
PTNS + temporary SNS no adverse events + 
permanent SNS with adverse events, ≥50% 
improvement 19,848.72 3,894.26 gamma 25.9786 0.0013 
PTNS + temporary SNS no adverse events + 
permanent SNS with adverse events, no 
improvement 19,012.20 3,733.41 gamma 25.9331 0.0014 
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